Clinical trial · Expanded Access

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations

NCT04087876CI-TRIAL-00088224no longer availableClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical development of derazantinib was ongoing.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Intrahepatic Cholangiocarcinoma	Intrahepatic Cholangiocarcinoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
derazantinib	Drug	Derazantinib	ALIAS

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

The following inclusion criteria were applied:

* all other treatment options had been exhausted
* patient was ineligible for any ongoing trials or was geographically inaccessible to trials including a trial with derazantinib
* there was a reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product
* patient was willing and able to provide written informed consent
* if applicable, regulatory approval by the appropriate jurisdiction was obtained

References

Publications (0)

Data not yet available

No reference posted for this study.